
Applied Molecular Transport AMTI
Quarterly report 2023-Q3
added 11-09-2023
Applied Molecular Transport P/CF Ratio 2011-2026 | AMTI
Annual P/CF Ratio Applied Molecular Transport
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.236 | -2.99 | -19 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.236 | -19 | -7.4 |
P/CF Ratio of other stocks in the Biotechnology industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.654 | - | 2.43 % | $ 254 M | ||
|
Assembly Biosciences
ASMB
|
-7.51 | $ 30.08 | 5.69 % | $ 337 M | ||
|
Ascendis Pharma A/S
ASND
|
-17.6 | $ 223.99 | 0.95 % | $ 5 B | ||
|
Autolus Therapeutics plc
AUTL
|
-2.05 | $ 1.41 | 2.55 % | $ 360 M | ||
|
Axsome Therapeutics
AXSM
|
-92.9 | $ 158.23 | 0.83 % | $ 7.87 B | ||
|
I-Mab
IMAB
|
-0.266 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
11.6 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.68 K | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-23.1 | - | -13.47 % | $ 169 M | ||
|
Gilead Sciences
GILD
|
18.3 | $ 138.83 | 1.18 % | $ 173 B | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-0.212 | $ 0.58 | -3.33 % | $ 540 K | ||
|
Midatech Pharma plc
MTP
|
-13.2 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.88 | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.64 | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
-8.36 | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-4.82 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-0.0018 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-1.2 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
-5 | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-1.71 | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
-2.73 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
-89 | - | - | - | ||
|
Grifols, S.A.
GRFS
|
14.1 | $ 7.75 | 2.24 % | $ 6.83 B | ||
|
Avenue Therapeutics
ATXI
|
-0.0603 | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
-0.826 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-0.401 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-0.0633 | - | -9.65 % | $ 45.9 M | ||
|
Compugen Ltd.
CGEN
|
6.2 | $ 2.14 | 2.39 % | $ 200 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-0.224 | - | - | $ 7.46 M | ||
|
AbCellera Biologics
ABCL
|
-7.33 | $ 3.45 | 1.47 % | $ 1.03 B | ||
|
Atreca
BCEL
|
-0.607 | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
7.5 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
-1.8 K | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
-14.5 | - | -10.95 % | $ 876 K | ||
|
Harmony Biosciences Holdings
HRMY
|
4.62 | $ 28.15 | 1.55 % | $ 1.62 B | ||
|
Cara Therapeutics
CARA
|
-0.588 | - | -3.03 % | $ 260 M | ||
|
Heron Therapeutics
HRTX
|
-7.19 | $ 0.8 | 3.3 % | $ 133 M | ||
|
ChemoCentryx
CCXI
|
-0.024 | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
-4.42 | - | -74.18 % | $ 955 K | ||
|
Coherus BioSciences
CHRS
|
-1.63 | $ 1.57 | 2.96 % | $ 184 M | ||
|
Checkpoint Therapeutics
CKPT
|
-5.15 | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
-1.18 | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-4.6 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-4.82 | - | - | $ 867 M | ||
|
Immunovant
IMVT
|
-6 | $ 23.9 | 4.0 % | $ 3.62 B | ||
|
Incyte Corporation
INCY
|
13.8 | $ 92.2 | 1.56 % | $ 18 B | ||
|
Akero Therapeutics
AKRO
|
-14.1 | - | - | $ 3.67 B | ||
|
InMed Pharmaceuticals
INM
|
-0.235 | $ 0.79 | -3.39 % | $ 1.93 M | ||
|
INmune Bio
INMB
|
-17.6 | $ 1.17 | - | $ 21 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-5.18 | $ 4.51 | 6.37 % | $ 748 M |